title: Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
abstract: OBJECTIVE
  To evaluate increased serum soluble interleukin-2 receptor (sIL-2R) levels in patients with renal cell carcinoma (RCC).
  
  
  METHODS
  Serum sIL-2R levels were measured in 52 patients with RCC and 10 control subjects by an enzyme-linked immunosorbent assay (ELISA) technique. The correlation between serum sIL-2R levels and clinical stage, disease prognostic value, and inflammatory marker levels was analyzed.
  
  
  RESULTS
  Serum sIL-2R levels in patients with RCC were significantly higher than those in normal control subjects (857.2 +/- 660.0 versus 291.3 +/- 76.4 U/mL, P < 0.0001). High serum sIL-2R levels appeared to be related to advanced clinical stage (596.0 +/- 276.5 U/mL in Stage II, 776.1 +/- 398.8 U/mL in Stage III, and 1310.0 +/- 926.7 U/mL in Stage IV: Stage II vs. Stage III, P = 0.0078; Stage II vs. Stage IV, P < 0.0001). The overall cause-specific survival curves showed that patients with high sIL-2R levels (more than 1000 U/mL) had a significantly lower survival rate than those with low (less than 500 U/mL, P = 0.0003) or intermediate levels (500 to 1000 U/mL, P = 0.0007). C-reactive protein levels apparently increased in patients with high sIL-2R concentrations.
  
  
  CONCLUSIONS
  Measurement of serum sIL-2R concentrations in patients with RCC provides useful information for predicting the extent of disease and length of survival.
authors.affiliation: Department of Urology, Taijukai Kaisei Hospital, Sakaide, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
authors.forename: A
authors.initials: A
authors.lastname: Furukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Sumiyoshi
authors.forename: K Y
authors.initials: KY
authors.lastname: Akiyama
authors.forename: H O
authors.initials: HO
authors.lastname: Kanayama
authors.forename: S
authors.initials: S
authors.lastname: Kagawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007680:Kidney Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015375:Receptors, Interleukin-2 / Q000097:blood*; D015996:Survival Rate
chemical_list: D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D002097:C-Reactive Protein